MedPath
HSA Approval

CILENTRA 10 ESCITALOPRAM OXALATE TABLET USP 10MG

SIN17140P

CILENTRA 10 ESCITALOPRAM OXALATE TABLET USP 10MG

CILENTRA 10 ESCITALOPRAM OXALATE TABLET USP 10MG

November 15, 2024

RANBAXY (MALAYSIA) SDN. BHD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantRANBAXY (MALAYSIA) SDN. BHD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

N06AB10

Manufacturer Information

RANBAXY (MALAYSIA) SDN. BHD.

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Active Ingredients

Escitalopram Oxalate eqv Escitalopram

10mg

Escitalopram

Documents

Package Inserts

Cilentra Tablet PI.pdf

Approved: November 15, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.